drugset / Trial / NCT05665075
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML). The clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 19 patients will be enrolled.
Timeline
- Start
- 2022-12-24
- Primary completion
- 2023-12-24
- Completion
- 2025-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QN-023a | Cell therapy | — | — |
| Background | Cyclophosphamid | Unknown | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |